ATE495756T1 - Verfahren zur herstellung humaner antikörper, die die biologische wirkung eines humanen cytokins blockieren - Google Patents

Verfahren zur herstellung humaner antikörper, die die biologische wirkung eines humanen cytokins blockieren

Info

Publication number
ATE495756T1
ATE495756T1 AT04816198T AT04816198T ATE495756T1 AT E495756 T1 ATE495756 T1 AT E495756T1 AT 04816198 T AT04816198 T AT 04816198T AT 04816198 T AT04816198 T AT 04816198T AT E495756 T1 ATE495756 T1 AT E495756T1
Authority
AT
Austria
Prior art keywords
activity
block
biological effect
human
human antibodies
Prior art date
Application number
AT04816198T
Other languages
English (en)
Inventor
Bernard Bizzini
Daniel Zagury
Buanec Helene Le
Original Assignee
Neovacs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neovacs filed Critical Neovacs
Application granted granted Critical
Publication of ATE495756T1 publication Critical patent/ATE495756T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04816198T 2003-09-16 2004-09-15 Verfahren zur herstellung humaner antikörper, die die biologische wirkung eines humanen cytokins blockieren ATE495756T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0350543A FR2859725B1 (fr) 2003-09-16 2003-09-16 Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
PCT/FR2004/050436 WO2005028513A2 (fr) 2003-09-16 2004-09-15 Procede a haut rendement pour l’obtention d’anticorps humains neutralisant l’activite biologique d’une cytokine humaine

Publications (1)

Publication Number Publication Date
ATE495756T1 true ATE495756T1 (de) 2011-02-15

Family

ID=34203543

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04816198T ATE495756T1 (de) 2003-09-16 2004-09-15 Verfahren zur herstellung humaner antikörper, die die biologische wirkung eines humanen cytokins blockieren

Country Status (12)

Country Link
US (1) US8679483B2 (de)
EP (2) EP2105448A3 (de)
JP (1) JP5095210B2 (de)
CN (1) CN1882610A (de)
AT (1) ATE495756T1 (de)
CA (1) CA2539172C (de)
DE (1) DE602004031133D1 (de)
DK (1) DK1668036T3 (de)
ES (1) ES2358118T3 (de)
FR (1) FR2859725B1 (de)
IL (1) IL174356A0 (de)
WO (1) WO2005028513A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20060560A1 (es) * 2004-08-03 2006-06-27 Novartis Ag Anticuerpos de interleucina-4 humana
HUE028379T2 (en) * 2006-09-29 2016-12-28 Oncomed Pharm Inc Preparations and procedures for the diagnosis and treatment of cancer
US8883145B2 (en) 2009-10-16 2014-11-11 Oncomed Pharmaceuticals, Inc. Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
WO2012056661A1 (ja) 2010-10-25 2012-05-03 パナソニック株式会社 電子部品の接合形態
EP2508197A1 (de) * 2011-04-07 2012-10-10 Neovacs Verfahren zur Behandlung IFN-alpha-assoziierter Erkrankungen
CN103608031B (zh) * 2011-04-07 2016-08-17 尼奥瓦克斯公司 用于治疗IFNα相关病况的方法
SI3485903T1 (sl) 2011-09-23 2023-02-28 Mereo Biopharma 5, Inc. Sredstva, ki vežejo VEGF/DLL4, in njihove uporabe
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US20160176962A1 (en) 2014-10-31 2016-06-23 Oncomed Pharmaceuticals, Inc. Combination Therapy For Treatment Of Disease
ES2968074T3 (es) 2015-09-23 2024-05-07 Mereo Biopharma 5 Inc Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4716111A (en) * 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB2218703B (en) * 1988-05-10 1992-10-28 Sumitomo Chemical Co Human monoclonal antibody to p.aeruginosa: its production and use
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
FR2677654B1 (fr) * 1991-06-17 1995-11-17 Pasteur Merieux Serums Vacc Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv.
EP0605522B1 (de) 1991-09-23 1999-06-23 Medical Research Council Methoden zur Herstellung humanisierter Antikörper
CA2101148A1 (en) 1992-07-23 1994-01-24 Hugette Cohen Purification of hapten-carrier generated antibodies
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
DE69420137T2 (de) * 1993-06-03 1999-12-23 Therapeutic Antibodies, Inc. Herstellung von antikörperfragmenten
AU3632595A (en) * 1994-09-15 1996-03-29 Verigen, Inc Porcine antibodies to tnf-alpha(alpha)
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
HU230048B1 (hu) * 1996-02-09 2015-06-29 Abbvie Biotechnology Ltd Humán TNFalfa-kötő antitestek alkalmazása
IL132240A0 (en) * 1997-04-07 2001-03-19 Genentech Inc Anti-vegf antibodies
EP2168984B1 (de) 1999-03-25 2012-08-29 Abbott GmbH & Co. KG Humane Antikörper die humanes IL-12 binden und Herstellungsverfahren
JP2001011096A (ja) * 1999-06-28 2001-01-16 Maruho Co Ltd 淋菌に対するヒト抗体
FR2812813B1 (fr) * 2000-08-09 2004-11-26 Neovacs Utilisation d'immunogenes pour traiter ou prevenir au sein des tumeurs malignes les dereglements immunitaires induits par des facteurs extracellulaires
US6709655B2 (en) 2001-02-28 2004-03-23 Instituto Bioclon, S.A. De C.V. Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
JP2002316944A (ja) * 2001-04-17 2002-10-31 Chemo Sero Therapeut Res Inst ヒトポリクローナル抗体組成物
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
FR2838444B1 (fr) 2002-04-10 2016-01-01 Neovacs Nouveaux peptides et leur application en therapeutique
GB0213878D0 (en) * 2002-06-17 2002-07-31 Protherics Plc Use
ATE472556T1 (de) * 2002-12-02 2010-07-15 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen

Also Published As

Publication number Publication date
CA2539172A1 (fr) 2005-03-31
WO2005028513A2 (fr) 2005-03-31
IL174356A0 (en) 2006-08-01
EP2105448A2 (de) 2009-09-30
DK1668036T3 (da) 2011-05-09
EP1668036B1 (de) 2011-01-19
FR2859725A1 (fr) 2005-03-18
US20070202102A1 (en) 2007-08-30
JP5095210B2 (ja) 2012-12-12
EP2105448A3 (de) 2012-11-14
FR2859725B1 (fr) 2006-03-10
US8679483B2 (en) 2014-03-25
EP1668036A2 (de) 2006-06-14
WO2005028513A3 (fr) 2005-07-21
CN1882610A (zh) 2006-12-20
ES2358118T3 (es) 2011-05-05
DE602004031133D1 (de) 2011-03-03
JP2007533622A (ja) 2007-11-22
CA2539172C (fr) 2015-07-14

Similar Documents

Publication Publication Date Title
DE602004031133D1 (de) Verfahren zur herstellung humaner antikörper, die die biologische wirkung eines humanen cytokins blockieren
ATE513905T1 (de) Verfahren für die replikation von influenza in zellkultur, und die bei diesem verfahren hergestellten influenza viren
EA200701377A1 (ru) Имплантируемый биоматериал и способ его получения
ATE469179T1 (de) Hydrogel
ATE314395T1 (de) Humanisierte antikörper und verfahren zu ihrer herstellung
DE60022678D1 (de) Verfahren zur herstellung eines geträgerten katalysatorsystems und dessen verwendung in einem polymerisationsverfahren
BRPI0410467A (pt) composições e métodos para tratamento de sìndrome respiratória aguda severa (sars)
DE69939312D1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
ATE413139T1 (de) Vorrichtung zur herstellung von anastomosen zwischen hohlorganen
MXPA06014465A (es) Zcytor14 soluble, anticuerpos anti-zcytor14 y moleculas de union y metodos de uso en inflamacion.
DE60040190D1 (de) Hydrogel zusammensetzungen, geeignet zur verzögerten freisetzung von makromolekülen sowie verfahren zur herstellung derselben.
WO2003046009A1 (en) ANTI-IL13 RECEPTOR α1 NEUTRALIZING ANTIBODY
WO2006025028A3 (en) Novel classification method of blood cells and tailor-made therapy and prevention based thereupon
ATE344321T1 (de) Verfahren zur aufreinigung von bakterienzellen und zellbestandteilen
ATE512752T1 (de) Verfahren zum herstellen eines lufthartbaren edelstahlrohres
EP4509608A4 (de) Capped-rna und verfahren zur herstellung davon, vorrichtung zur herstellung von protein und verfahren zur herstellung von protein
DE50102671D1 (de) Diethyloctandioldicarbamate und diethyloctandioldiallophanate, verfahren zu ihrer herstellung und ihre verwendung
ATE474874T1 (de) Verfahren zur herstellung von polyetheralkoholen
FR2834620B1 (fr) Procede et installation pour la preparation de tetes de salade
ATE391115T1 (de) Verfahren zur herstellung von diketenacetalen
DE69617956D1 (de) Zusammensetzungen, welche adp-ribosyltransferase-aktivität aufweisen und methoden für ihre herstellung und die verwendung derselben
PT1207917E (pt) Selante para proteses vasculares
ATE496054T1 (de) Verfahren zur herstellung von 1,3-dioxolan- nucleosiden
Bokholm Stadernas handlingsfrihet: En studie av expansionsskedet, 1900-1930.
DE69917440D1 (de) 5-imino-13-deoxy-antracyclin-derivate, ihre verwendung sowie verfahren zu deren herstellung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1668036

Country of ref document: EP